Sleep Number (SNBR) Q2 Revenue Falls 20%

Sleep Number (SNBR) reported a challenging Q2 2025, with GAAP revenue falling 19.7% year-over-year to $327.9 million, significantly missing analyst estimates, and its net loss deepening to $(1.09) per share, well beyond forecasts. While gross margin remained stable at 59.1% despite the sales decline, management attributed the revenue slump to deliberate reductions in marketing spend as part of a strategic reset. The company also reported negative free cash flow and a leverage ratio of 4.56x EBITDAR, approaching its maximum covenant, with full-year guidance forecasting a 14% net sales decline, signaling continued operational headwinds and a transitional period.

Analysis

Sleep Number (SNBR) reported a significantly challenged second quarter for fiscal 2025, characterized by a severe top-line contraction and deteriorating profitability. GAAP revenue fell 19.7% year-over-year to $327.9 million, missing analyst consensus by over 8%, a decline management attributed to a deliberate and aggressive reduction in marketing expenditures. This strategic marketing reset has, in the short term, failed to stabilize sales, as evidenced by an 18% drop in retail comparable-store sales. Despite the revenue slump, the company demonstrated operational discipline by maintaining its gross profit margin at 59.1%, consistent with the prior year, and reducing operating expenses by 21%. However, these efficiencies were insufficient to prevent a dramatic widening of the net loss to $(1.09) per share, far exceeding the forecasted loss of $(0.11). The financial position has become precarious, with free cash flow turning negative to $(6.9) million from a positive $9.4 million a year ago, and the leverage ratio rising to 4.56x EBITDAR, nearing the maximum allowed by its debt covenants. The full-year outlook offers little reprieve, forecasting a 14% annual sales decline, signaling that management expects continued headwinds before the new strategy yields positive results.

Key Decisions for Investors

• Investors must closely monitor the company's leverage ratio of 4.56x EBITDAR, as any further deterioration creates a significant risk of breaching debt covenants and jeopardizing solvency.
• The investment case is now a high-risk turnaround play dependent on the success of a marketing strategy reset and a $130 million cost-saving initiative; progress toward break-even free cash flow in the second half of 2025 will be a critical validation point.
• Given the forecasted 14% full-year revenue decline and the absence of new product or partnership catalysts, investors should remain cautious, as the stock is highly sensitive to any signs of failure in management's turnaround efforts or further weakening in consumer demand.